Hospital
Adventist Health System-Sunbelt INC
Adventist Health System-Sunbelt INC was paid $7.54M by Medicaid between Jan 2018 and Dec 2024, across 100 billing codes. Its largest line is 99283, emergency room visit (moderate) — 27% of everything it billed.
33Billing provider infoADVENTIST HEALTH SYSTEM-SUNBELT INC
WAUCHULA, FL 33873
WAUCHULA, FL 33873
33aNPI1275511651assigned 01/05/2006
33bProvider typeCritical Access Hospital
28Total paid$7.54M
24GClaims140,115
24DCodes billed100
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Florida
Rank by total paid#2 of 12
Median peer was paid$3.14M
This provider vs. median2.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 8,270 | $280K | |
| 2019 | 24,329 | $959K | |
| 2020 | 25,644 | $1.19M | |
| 2021 | 30,825 | $1.60M | |
| 2022 | 27,719 | $1.65M | |
| 2023 | 18,265 | $1.31M | |
| 2024incomplete | 5,063 | $555K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 27% | 16,342 | 15,103 | $2.04M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 10,052 | 9,083 | $1.33M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.1% | 4,391 | 3,865 | $537K |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.7% | 3,590 | 3,173 | $433K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.6% | 4,263 | 3,780 | $350K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.6% | 1,207 | 1,118 | $348K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.5% | 2,933 | 2,679 | $342K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 3.7% | 1,615 | 1,476 | $280K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.4% | 1,281 | 1,170 | $254K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.9% | 999 | 908 | $219K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.4% | 2,340 | 2,238 | $177K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.8% | 2,825 | 2,515 | $133K |
88 more codes
| 80053 | Comprehensive metabolic panel | 1.6% | 9,608 | $118K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 480 | $98K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 1,107 | $89K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.1% | 881 | $83K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 885 | $63K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,038 | $61K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,580 | $55K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 771 | $36K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 11,141 | $34K |
| 81003 | <1% | 2,317 | $31K | |
| 81025 | <1% | 2,151 | $31K | |
| 81001 | <1% | 5,372 | $30K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 831 | $30K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,888 | $28K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,442 | $22K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 679 | $20K |
| 36415 | Collection of venous blood by venipuncture | <1% | 838 | $19K |
| 80050 | General health panel | <1% | 549 | $18K |
| 73630 | <1% | 239 | $18K | |
| 73564 | <1% | 298 | $16K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,068 | $15K |
| 84484 | <1% | 3,075 | $13K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,103 | $12K |
| 74018 | <1% | 253 | $12K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 307 | $12K |
| 82947 | <1% | 833 | $9K | |
| 83605 | <1% | 1,803 | $8K | |
| 73610 | <1% | 106 | $8K | |
| 83690 | <1% | 2,208 | $8K | |
| 87040 | <1% | 1,711 | $8K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,306 | $6K |
| 83880 | <1% | 506 | $6K | |
| 85610 | <1% | 905 | $5K | |
| 87186 | <1% | 911 | $5K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,393 | $5K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 71 | $4K |
| 80061 | Lipid panel | <1% | 1,119 | $4K |
| 73130 | <1% | 53 | $4K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 863 | $4K |
| 87420 | <1% | 89 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,108 | $3K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 12 | $3K |
| 73030 | <1% | 42 | $3K | |
| 85730 | <1% | 510 | $3K | |
| 84702 | <1% | 227 | $3K | |
| 87077 | <1% | 667 | $3K | |
| 83735 | <1% | 544 | $3K | |
| 84439 | <1% | 481 | $2K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 12 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,111 | $2K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 399 | $2K |
| 87634 | <1% | 12 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 640 | $1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 38 | $1K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 12 | $1K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,085 | $900.84 |
| 82803 | <1% | 17 | $721.85 | |
| 36600 | <1% | 17 | $721.85 | |
| 72110 | <1% | 24 | $559.79 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 47 | $521.26 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 83 | $415.79 |
| 73110 | <1% | 16 | $297.52 | |
| 83540 | <1% | 25 | $257.89 | |
| 86140 | <1% | 172 | $232.52 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 30 | $200.86 |
| 85651 | <1% | 169 | $109.10 | |
| 85380 | <1% | 89 | $103.86 | |
| 82077 | <1% | 26 | $84.96 | |
| 82607 | <1% | 30 | $81.45 | |
| 85027 | <1% | 30 | $73.29 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 14 | $68.51 |
| 86780 | <1% | 24 | $64.22 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 99 | $44.20 |
| 82728 | <1% | 26 | $41.46 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 710 | $25.94 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 12 | $25.47 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 118 | $19.49 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 36 | $12.12 |
| 86901 | <1% | 13 | $6.48 | |
| 84703 | <1% | 301 | $4.92 | |
| 85652 | <1% | 18 | $2.73 | |
| 82570 | <1% | 13 | $2.46 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 209 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 145 | $0.00 |
| 86900 | 0% | 13 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 26 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 33 | $0.00 |
| 84145 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDUNKEL, JASON (CEO)
| Provider | Location | Paid |
|---|---|---|
| Adventist Health System-Sunbelt INC | Wauchula, FL | $11.13M |
| Adventist Health System-Sunbelt INC | Wauchula, FL | $345K |
| Adventist Health System-Sunbelt INC | Avon Park, FL | $235K |
| Adventist Health System-Sunbelt INC | Frostproof, FL | $21K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.